Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYT 6091

Next Previous
X
Search
Drug Profile

CYT 6091

Alternative Names: AURIMUNE; Aurimune-T; CYT-6091

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytImmune Sciences
  • Class Antineoplastics; Tumour necrosis factors
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
  • 23 Aug 2022 CYT 6091 is still in phase-I trials for Solid-tumours in USA (IV, Injection) (CytImmune Sciences pipeline, August 2022)
  • 23 Aug 2022 National Cancer Institute (USA) enters into clinical trial agreement with CytImmune Sciences to conduct phase Ib and multiple phase II clinical trials prior to August 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top